Will Neuralink get approval for a second Canadian trial by November 2025? | Binary | | | 1 month ago | |
Will Neuralink complete its first Canadian clinical trial by end of 2025? | Binary | | | 1 month ago | |
Will another mRNA-based RSV vaccine be approved in Canada for adults 60+ by Dec 31, 2025? | Binary | | | 2 months ago | |
Will Neuralink complete recruitment for its first Canadian clinical trial by June 30, 2025? | Binary | | | 1 month ago | |
Will Moderna's stock price increase by 10% or more by Dec 31, 2024, after Health Canada approval? | Binary | | | 2 months ago | |
Asciminib (Scemblix) major molecular response rate by end of 2025? | Categorical | | | 2 months ago | |
Asciminib (Scemblix) market share over 30% in US by end of 2025? | Binary | | | 2 months ago | |
What will be the primary outcome of Neuralink's CAN-PRIME trial by end of 2025? | Categorical | | | 28 days ago | |
What will Neuralink's next step be after CAN-PRIME trial completion by mid-2026? | Categorical | | | 28 days ago | |
How many participants will complete Neuralink's CAN-PRIME trial by end of 2025? | Categorical | | | 28 days ago | |
Will Neuralink's CAN-PRIME trial show significant improvement in patient outcomes by end of 2025? | Binary | | | 28 days ago | |
Will Health Canada approve broader clinical trials for Neuralink's N1 Implant by end of 2025? | Binary | | | 28 days ago | |
Will Neuralink complete the CAN-PRIME trial in Canada by end of 2025? | Binary | | | 28 days ago | |
What will be the primary challenge in Neuralink's Canadian trials by end of 2025? | Categorical | | | 1 month ago | |
Will Neuralink's N1 chip show initial functionality in Canadian trial participants by mid-2025? | Binary | | | 1 month ago | |
Will Neuralink expand its Canadian trials to other hospitals by end of 2025? | Binary | | | 1 month ago | |
When will the first Canadian participant use N1 chip for device control by end of 2025? | Categorical | | | 1 month ago | |
Will Neuralink's Canadian trial show significant mobility improvement by 2025? | Binary | | | 1 month ago | |
What will be the outcome of Neuralink's first Canadian trial by end of 2025? | Categorical | | | 1 month ago | |
What regulatory action will Health Canada take on Neuralink's trial by November 2025? | Categorical | | | 1 month ago | |
How many participants will Neuralink recruit for Canadian trial by June 2025? | Categorical | | | 1 month ago | |
What major partnership will result from Neuralink's N1 chip trial in Canada by end of 2025? | Categorical | | | 1 month ago | |
What milestone will Neuralink's first Canadian N1 chip trial reach by end of 2025? | Categorical | | | 1 month ago | |
Will Neuralink's N1 chip trial in Canada show positive results by end of 2025? | Binary | | | 1 month ago | |
What regulatory change will result from Neuralink's N1 chip trial in Canada by end of 2025? | Categorical | | | 1 month ago | |
Will Neuralink receive approval to expand Canadian trials beyond ALS and SCI by end of 2025? | Binary | | | 1 month ago | |
Will Moderna's mRESVIA RSV Vaccine be approved by the EMA for adults 60+ by June 30, 2025? | Binary | | | 2 months ago | |
How many doses of mRESVIA RSV Vaccine will be administered in Canada by Nov 8, 2025? | Categorical | | | 2 months ago | |
Which major country will approve mRESVIA RSV Vaccine first after Canada by Dec 31, 2025? | Categorical | | | 2 months ago | |
What will be the market share of mRESVIA RSV Vaccine in Canada by Nov 8, 2025? | Categorical | | | 2 months ago | |
Major adverse effects reported for Asciminib (Scemblix) in US by October 2025? | Binary | | | 2 months ago | |
Health Canada approval for Asciminib (Scemblix) by March 31, 2025? | Binary | | | 2 months ago | |
Main competitor to Asciminib (Scemblix) in US by end of 2025? | Categorical | | | 2 months ago | |
Next region to approve Asciminib (Scemblix) after US by end of 2025? | Categorical | | | 2 months ago | |
Which COVID-19 vaccine targeting the KP.2 variant will be most administered in the US by December 31, 2024? | Categorical | | | 3 months ago | |
Which COVID-19 vaccine targeting the KP.2 variant will be most effective in reducing viral load by December 31, 2024? | Categorical | | | 3 months ago | |
Which COVID-19 vaccine targeting the KP.2 variant will be perceived to have the fewest side effects by the public by December 31, 2024? | Categorical | | | 3 months ago | |
Will at least 10 million doses of Moderna's updated KP.2 variant vaccine be administered in the US by December 31, 2024? | Binary | | | 3 months ago | |
Will Moderna's updated KP.2 variant vaccine be available at major retailers by October 31, 2024? | Binary | | | 3 months ago | |
Will studies confirm that Novavax has fewer side effects than Moderna by December 31, 2024? | Binary | | | 3 months ago | |